Ectomesenchymal Stem Cell Isolation for Sustained Regenerative Potency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing mesenchymal stem cells (MSCs) used in regenerative medicine lose their proliferation ability and multi-lineage differentiation potency when continuously cultured in vitro, necessitating the development of a more effective therapeutic method and a cell with higher tissue regeneration potential.
Innovation Solution
The discovery and utilization of ectomesenchymal stem cells (EMSCs) induced by necrotic tissue injury, mobilized by a peptide (HA1-44) to accumulate in peripheral blood, and a method for producing and screening multipotent stem cell inducers using PDGFRα-positive cells, which exhibit enhanced differentiation potency into bone, cartilage, and fat.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional mesenchymal stem cells are continuously cultured in vitro, then they can be used for regenerative medicine, but they gradually lose their proliferation ability and multi-lineage differentiation potency
Solution Approach 1:
The invention extracts and identifies a specific subpopulation of mesenchymal stem cells (PDGFRα-positive cells) from the heterogeneous MSC population that possesses enhanced proliferation ability and multi-lineage differentiation potency. This extraction of the functional subset resolves the contradiction by providing a reliable cell source that maintains its regenerative capacity even after continuous in vitro passage.
Solution Approach 2:
The invention applies local quality by characterizing and isolating mesenchymal stem cells with specific surface marker expression patterns (PDGFRα-positive, CD34-negative, Sca-1-negative). This localized identification of cells with superior functional properties allows for the selection of a subpopulation that maintains high proliferation and differentiation capacity throughout continuous culture, thereby resolving the reliability-duration contradiction.
2Reliability
If a specific cell population is selected for regenerative therapy, then therapeutic effectiveness is improved, but the complexity of cell identification and isolation increases
Solution Approach 1:
The invention utilizes parameter changes by establishing a specific phenotypic profile (PDGFRα-positive, CD34-negative, Sca-1-negative) as selection criteria for high-potency mesenchymal stem cells. This parameter-based identification system enables reliable isolation of therapeutically effective cells while maintaining procedural simplicity, as the surface marker status can be detected using standard flow cytometry or magnetic-activated cell sorting techniques.
Data Source
AI summary
The inventors discovered that ectodermal mesenchymal stem cells circulating in peripheral blood that are induced by necrotic tissue damage contribute to the regeneration of damaged tissue. On the basis of this discovery, provided are ectodermal mesenchymal stem cells, a method for producing the same, and a screening method for a substance having pluripotent stem cell inductive activity, the screening method using cells induced by necrotic tissue damage in peripheral blood as an index.